BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $74.47, for a total value of $279,262.50. Following the completion of the sale, the director now owns 27,340 shares of the company’s stock, valued at $2,036,009.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

BMRN traded down $0.33 during midday trading on Thursday, reaching $75.17. 12,874 shares of the company were exchanged, compared to its average volume of 955,794. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.79 and a current ratio of 4.11. BioMarin Pharmaceutical Inc. has a one year low of $70.82 and a one year high of $106.74. The stock has a market capitalization of $13.53 billion, a P/E ratio of -226.89 and a beta of 1.32. The stock’s 50-day simple moving average is $75.31 and its 200 day simple moving average is $83.43.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The company had revenue of $388.00 million for the quarter, compared to the consensus estimate of $415.03 million. During the same quarter last year, the business posted ($0.09) EPS. BioMarin Pharmaceutical’s quarterly revenue was up 4.0% on a year-over-year basis. On average, research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.03 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its holdings in BioMarin Pharmaceutical by 21.8% during the second quarter. Janus Henderson Group PLC now owns 55,613 shares of the biotechnology company’s stock worth $4,764,000 after buying an additional 9,953 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 66.3% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 104,970 shares of the biotechnology company’s stock valued at $8,991,000 after purchasing an additional 41,856 shares in the last quarter. Jennison Associates LLC lifted its holdings in shares of BioMarin Pharmaceutical by 7.0% during the 1st quarter. Jennison Associates LLC now owns 12,412,593 shares of the biotechnology company’s stock valued at $1,102,611,000 after purchasing an additional 812,133 shares in the last quarter. IMA Wealth Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 1.8% during the 1st quarter. IMA Wealth Inc. now owns 39,659 shares of the biotechnology company’s stock valued at $3,523,000 after purchasing an additional 704 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of BioMarin Pharmaceutical during the 1st quarter valued at about $948,000. Hedge funds and other institutional investors own 97.93% of the company’s stock.

A number of brokerages recently commented on BMRN. Wedbush reiterated an “outperform” rating and issued a $128.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, July 10th. Citigroup reiterated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, May 23rd. BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday. Piper Jaffray Companies set a $120.00 price objective on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $133.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, August 5th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $115.33.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: Market Capitalization

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.